Artal Group S.a. buys $26,792,000 stake in Agios Pharmaceuticals Inc (AGIO)

Agios Pharmaceuticals Inc (AGIO) : Artal Group S.a. scooped up 25,000 additional shares in Agios Pharmaceuticals Inc during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Nov 14, 2016. The investment management firm now holds a total of 400,000 shares of Agios Pharmaceuticals Inc which is valued at $26,792,000.Agios Pharmaceuticals Inc makes up approximately 0.69% of Artal Group S.a.’s portfolio.

Other Hedge Funds, Including , Clearbridge Investments reduced its stake in AGIO by selling 1,524 shares or 0.1% in the most recent quarter. The Hedge Fund company now holds 1,458,751 shares of AGIO which is valued at $97,707,142. Agios Pharmaceuticals Inc makes up approx 0.11% of Clearbridge Investments’s portfolio. Marshall Wace Llp added AGIO to its portfolio by purchasing 107,423 company shares during the most recent quarter which is valued at $6,850,365. Agios Pharmaceuticals Inc makes up approx 0.05% of Marshall Wace Llp’s portfolio.Blackrock Investment Management boosted its stake in AGIO in the latest quarter, The investment management firm added 6,759 additional shares and now holds a total of 29,935 shares of Agios Pharmaceuticals Inc which is valued at $1,565,301.Blackrock Advisors boosted its stake in AGIO in the latest quarter, The investment management firm added 132,724 additional shares and now holds a total of 385,747 shares of Agios Pharmaceuticals Inc which is valued at $20,170,711. Agios Pharmaceuticals Inc makes up approx 0.02% of Blackrock Advisors’s portfolio.State Of Wisconsin Investment Board boosted its stake in AGIO in the latest quarter, The investment management firm added 1,300 additional shares and now holds a total of 19,770 shares of Agios Pharmaceuticals Inc which is valued at $954,693.

Agios Pharmaceuticals Inc closed down -0.27 points or -0.43% at $62.54 with 4,09,422 shares getting traded on Monday. Post opening the session at $62.72, the shares hit an intraday low of $62.07 and an intraday high of $63.55 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.

On the company’s financial health, Agios Pharmaceuticals Inc reported $-1.63 EPS for the quarter, missing the analyst consensus estimate by $ -0.12 based on the information available during the earnings call on Nov 3, 2016. Analyst had a consensus of $-1.51. The company had revenue of $8.98 million for the quarter, compared to analysts expectations of $8.64 million. The company’s revenue was up 63.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-1.07 EPS.

Many Wall Street Analysts have commented on Agios Pharmaceuticals Inc. Needham Initiated Agios Pharmaceuticals Inc on Oct 24, 2016 to “Buy”, Price Target of the shares are set at $60.

Agios Pharmaceuticals Inc. (Agios) is a biopharmaceutical company. The Company is engaged in the discovery and development of orally available small molecule medicines for the treatment of cancer and rare genetic disorders (RGDs) of metabolism using cellular metabolism as a platform. It is also engaged in the identification and validation of altered metabolic pathways within abnormal cells. Its products include AG-221 AG-120 and AG-348. Its lead product AG-348 in the RGD program is an orally available small molecule that targets pyruvate kinase-R for the treatment of pyruvate kinase deficiency. AG-221 is potent inhibitor of the mutated IDH2 protein being developed for the treatment hematological malignancies and advanced solid tumors. AG-120 is an orally available selective potent inhibitor of the mutated IDH1 protein being developed for the treatment hematological malignancies and advanced solid tumors.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Agios Pharmaceuticals Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on Agios Pharmaceuticals Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.